Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 9/20 | 0.41 |
| ▸ | CA2 | P00918 | 9/20 | 0.41 |
| ▸ | CA12 | O43570 | 6/20 | 0.41 |
| ▸ | CA9 | Q16790 | 6/20 | 0.41 |
| ▸ | STK17B | O94768 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3472122 | 0.99 | CA14 (0.62) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL4370840 | 0.97 | CA14 (0.59) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL14107661 | 0.96 | CA14 (0.56) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL14107562 | 0.96 | CA14 (0.56) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL7631999 | 0.96 | CA14 (0.62) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL5919555 | 0.96 | CA14 (0.58) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL19340291 | 0.94 | CA14 (0.57) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL25238320 | 0.93 | CA14 (0.56) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL17396373 | 0.93 | CA14 (0.56) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL7270004 | 0.93 | CA14 (0.58) | CA14TDP1MAOAMAOBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643301-B1 | TECHNETIUM-99M COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | PF MEDICAMENT (FR) | 2017-10-04 | — | — | EP | disclosed |
| EP-2326653-B1 | NEW (POLY)AMINOALKYLAMINOALKYL-UREA DERIVATIVES OF EPIPODOPHYLLOTOXIN, A PROCESS FOR PREPARING THEM, AND APPLICATION THEREOF IN THERAPY AS ANTICANCER AGENTS | PF MEDICAMENT (FR) | 2013-12-11 | — | — | EP | disclosed |
| US-8492567-B2 | (Poly)Aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents | PIERRE FABRE MEDICAMENT (FR) | 2013-07-23 | — | — | US | disclosed |
| US-20130171067-A1 | TECHNETIUM-99m COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| US-20120283281-A1 | NEW (POLY)AMINOALKYLAMINOALKYLAMIDE, ALKYL-UREA, OR ALKYL-SULFONAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN, A PROCESS FOR PREPARING THEM, AND APPLICATION THEREOF IN THERAPY AS ANTICANCER AGENTS | IMBERT THIERRY (FR) | 2012-11-08 | — | — | US | disclosed |
| US-8288567-B2 | (Poly) aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents | PIERRE FABRE MEDICAMENT (FR) | 2012-10-16 | — | — | US | disclosed |
| US-20110172257-A1 | (POLY) AMINOALKYLAMINOALKYLAMIDE, ALKYL-UREA, OR ALKYL-SULFONAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN, A PROCESS FOR PREPARING THEM, AND APPLICATION THEREOF IN THERAPY AS ANTICANCER AGENTS | PIERRE FABRE MEDICAMENT (FR) | 2011-07-14 | — | — | US | disclosed |
| EP-2326653-A1 | NEW (POLY)AMINOALKYLAMINOALKYLAMIDE, ALKYL-UREA, OR ALKYL-SULFONAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN, A PROCESS FOR PREPARING THEM, AND APPLICATION THEREOF IN THERAPY AS ANTICANCER AGENTS | Pierre Fabre Médicament (FR) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010020663-A1 | NEW (POLY)AMINOALKYLAMINOALKYLAMIDE, ALKYL-UREA, OR ALKYL-SULFONAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN, A PROCESS FOR PREPARING THEM, AND APPLICATION THEREOF IN THERAPY AS ANTICANCER AGENTS | PIERRE FABRE MEDICAMENT (FR) | 2010-02-25 | — | — | WO | disclosed |
| US-7411002-B2 | Polycationic sulfonamides and use thereof | THE UNIVERSITY OF KANSAS (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070287750-A1 | Polycationic sulfonamides and use thereof | THE UNIVERSITY OF KANSAS (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070197658-A1 | Polyamines and their use as antibacterial and sensitizing agents | KANSAS, UNIVERSITY OF | 2007-08-23 | — | — | US | disclosed |
| US-20070197658-A1 | Polyamines and their use as antibacterial and sensitizing agents | KANSAS, UNIVERSITY OF | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171067-A1 | TECHNETIUM-99m COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | SLC40A1, CDC73, BRCA1 | CA14 15/4885TDP1 1712/4885MAOA 2345/4885 |
| US-20070287750-A1 | Polycationic sulfonamides and use thereof | STS, PTDSS2, PTDSS1 | CA14 671/4885TDP1 3575/4885MAOA 4794/4885 |
| US-20110172257-A1 | (POLY) AMINOALKYLAMINOALKYLAMIDE, ALKYL-UREA, OR ALKYL-SULFONAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN, A PROCESS FOR PREPARING THEM, AND APPLICATION THEREOF IN THERAPY AS ANTICANCER AGENTS | CCNH, HCCS, KCNH1 | CA14 2174/4885TDP1 4046/4885MAOA 3160/4885 |
| US-20120283281-A1 | NEW (POLY)AMINOALKYLAMINOALKYLAMIDE, ALKYL-UREA, OR ALKYL-SULFONAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN, A PROCESS FOR PREPARING THEM, AND APPLICATION THEREOF IN THERAPY AS ANTICANCER AGENTS | NPEPPS, XPOT, UTS2R | CA14 3272/4885TDP1 2472/4885MAOA 3454/4885 |
| US-20070197658-A1 | Polyamines and their use as antibacterial and sensitizing agents | SRM, SMS, C9 | CA14 4622/4885TDP1 2763/4885MAOA 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.